Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Setanaxib plus pembrolizumab in recurrent or metastatic SCCHN
2021-004627-33Phase 2Active
- Sponsor
- Genkyotex
- Start
- Nov 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in head and neck squamous cell carcinoma (HNSCC) comparing Setanaxib + pembrolizumab with Placebo + pembrolizumab (2 arms). Primary endpoint: Best percentage change in tumour size. Started Nov 2021; status: active.
02
Drugs
setanaxibpembrolizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2021-004627-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004627-33.